GRI Bio stockholders voted to amend the company's Amended and Restated 2018 Equity Incentive Plan. The approval increases the number of common shares reserved for issuance by 546,529 and extends the evergreen provision through January 1, 2036. Directors were re-elected and the auditor was ratified. GRI Bio operates in the biotechnology industry.
